Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.
Cicin İ, Özatlı T, Türkmen E, Özturk T, Özçelik M, Çabuk D, Gökdurnalı A, Balvan Ö, Yıldız Y, Şeker M, Özdemir N, Yapar B, Tanrıverdi Ö, Günaydin Y, Menekşe S, Öksüzoğlu B, Aksoy A, Erdogan B, Bekir Hacıoglu M, Arpaci E, Sevinç A. Cicin İ, et al. Among authors: yildiz y. Balkan Med J. 2016 Sep;33(5):517-524. doi: 10.5152/balkanmedj.2016.151268. Epub 2016 Sep 1. Balkan Med J. 2016. PMID: 27761279 Free PMC article.
Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E, Karaca H, Koca S, Sevinç A, Hacioğlu B, Özkan M, Özçelik M, Duran AO, Hacibekiroğlu İ, Yildiz Y, Tanriverdi Ö, Menekşe S, Aksoy A, Bozkurt O, Urvay S, Uysal M, Demir H, Çiltaş A, Dane F. Özaslan E, et al. Among authors: yildiz y. Anticancer Drugs. 2017 Feb;28(2):222-229. doi: 10.1097/CAD.0000000000000445. Anticancer Drugs. 2017. PMID: 27768606
Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study.
Bilir C, Yıldız İ, Bilici A, Ucar M, Berk V, Yıldız Y, Yazıcı O, İmamoğlu Gİ, Karadurmuş N, Pilancı KN, Arpacı E, Tanrıverdi Ö, Karcı E, Temiz S, Nayır E, Oktay E, Dal P, Petekkaya İ, Varım C, Cinemre H. Bilir C, et al. Among authors: yildiz i, yildiz y. Cancer Invest. 2017 Apr 21;35(4):248-255. doi: 10.1080/07357907.2017.1292518. Epub 2017 Mar 23. Cancer Invest. 2017. PMID: 28333566
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.
Yildiz I, Bilici A, Karadurmuş N, Ozer L, Tural D, Kaplan MA, Akman T, Bayoglu IV, Uysal M, Yildiz Y, Tanriverdi Ö, Yazici O, Sürmeli Z, Serdar Turhal N, Bavbek S, Selçukbiricik F, Koca D, Basaran M. Yildiz I, et al. Among authors: yildiz y. Tumori. 2018 Dec;104(6):444-450. doi: 10.5301/tj.5000635. Epub 2018 May 9. Tumori. 2018. PMID: 28731496
Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
Taskaynatan H, Kucukzeybek Y, Alacacioglu A, Yildiz Y, Salman T, Oflazoglu U, Varol U, Bolat Kucukzeybek B, Kemal Atahan M, Oktay Tarhan M. Taskaynatan H, et al. Among authors: yildiz y. J BUON. 2018 Jul-Aug;23(4):877-882. J BUON. 2018. PMID: 30358189 Free article.
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A. Özdemir Ö, et al. Among authors: yildiz y. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20. Anticancer Drugs. 2022. PMID: 35703239
408 results